Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study - 18/04/17
, Charles A B Boucher, ProfPhD a, Marc van der Valk, PhD c, Bart J A Rijnders, PhD b, David A M C van de Vijver, PhD aSummary |
Background |
Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine prevents HIV infections among men who have sex with men (MSM). PrEP can be given on a daily or intermittent basis. Unfortunately, PrEP is not reimbursed in most European countries. Cost-effectiveness analyses of PrEP among MSM in Europe are absent but are key for decision makers to decide upon PrEP implementation.
Methods |
We developed a deterministic mathematical model, calibrated to the well defined Dutch HIV epidemic among MSM, to predict the effect and cost-effectiveness of PrEP. PrEP was targeted to 10% of highly sexually active Dutch MSM over the coming 40 years. Cost-effectiveness ratios were calculated to predict the cost-effectiveness of daily and on-demand PrEP. Cost-effectiveness ratios below €20 000 were considered to be cost-effective in this analysis.
Findings |
Within the context of a stable HIV epidemic, at 80% effectiveness and current PrEP pricing, PrEP can cost as much as €11 000 (IQR 9400–14 100) per quality-adjusted life-year (QALY) gained when used daily, or as little as €2000 (IQR 1300–3000) per QALY gained when used on demand. At 80% effectiveness, daily PrEP can be considered cost-saving if the price of PrEP is reduced by 70%, and on-demand PrEP can be considered cost-saving if the price is reduced by 30–40%.
Interpretation |
PrEP for HIV prevention among MSM in the Netherlands is cost-effective. The use of PrEP is most cost-effective when the price of PrEP is reduced through on-demand use or through availability of generic PrEP, and can quickly be considered cost-saving.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 16 - N° 12
P. 1423-1429 - décembre 2016 Retour au numéro
Article précédent
- Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses
- Kali Zhou, Thomas Fitzpatrick, Nick Walsh, Ji Young Kim, Roger Chou, Mellanye Lackey, Julia Scott, Ying-Ru Lo, Joseph D Tucker
- New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective
- Benedetta Allegranzi, Peter Bischoff, Stijn de Jonge, N Zeynep Kubilay, Bassim Zayed, Stacey M Gomes, Mohamed Abbas, Jasper J Atema, Sarah Gans, Miranda van Rijen, Marja A Boermeester, Matthias Egger, Jan Kluytmans, Didier Pittet, Joseph S Solomkin, WHO Guidelines Development Group †
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?